Barr, Organon Pen Mircette "Authorized Generic" Deal

Law360, New York (December 2, 2005, 12:00 AM EST) -- Pharmaceutical company Organon has given generics maker Barr Pharmaceuticals the green light to produce its own version of Organon’s Mircette, an oral contraceptive, becoming the latest in Barr’s string of authorized generics agreements.

The agreement, the terms of which have not been released, marks the end of patent litigation between the two companies initiated when Barr began marketing Kavira, a generic version of Mircette.

The two companies began the transaction in June, when they filed a letter with the Federal Trade Commission seeking approval of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.